Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.12.19
Views: 622
Rating:

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Prof Martine Piccart speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the updated six-year results from the APHINITY trial.

She gives a summary of the previous analyses, in which a statistically significant improvement in invasive disease-free survival, favouring the pertuzumab plus trastuzumab and chemotherapy arm.

Prof Piccart explains that this benefit has strengthened in the past six years and notes that a 4.5 percent absolute benefit has been seen in the node-positive patients. In addition, no new cardiac toxicities were detected.

She adds that the benefit of pertuzumab is independent from hormone-receptor status.

Prof Piccart believes that the achievement of this data is another step forward in eradicating this disease.

Watch the press conference here.

Read more about the study here

 

Related videos

18.02.20

no rating
Epidemiology of cancer in India

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation